These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 14576518)
1. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. Spindler M; Weilbach F; Beer M; Sandstede J; Köstler H; Strotmann J; Voelker W; Hahn D; Ertl G; Gold R J Cardiovasc Pharmacol; 2003 Nov; 42(5):680-7. PubMed ID: 14576518 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413 [TBL] [Abstract][Full Text] [Related]
3. Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis. Pattoneri P; Sozzi F; Pelà G; Montanari E; Moruzzi P; Borghetti A; Cappellini MD Echocardiography; 2009 Apr; 26(4):397-402. PubMed ID: 19017314 [TBL] [Abstract][Full Text] [Related]
4. Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction. Joyce E; Mulroy E; Scott J; Melling J; Goggin C; McGorrian C; O'Rourke K; Lynch T; Mahon N J Card Fail; 2013 Aug; 19(8):571-6. PubMed ID: 23910587 [TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
7. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis. Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472 [TBL] [Abstract][Full Text] [Related]
8. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Zingler VC; Nabauer M; Jahn K; Gross A; Hohlfeld R; Brandt T; Strupp M Eur Neurol; 2005; 54(1):28-33. PubMed ID: 16088176 [TBL] [Abstract][Full Text] [Related]
9. B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study. Luchowski P; Mitosek-Szewczyk K; Bartosik-Psujek H; Rubaj A; Jankiewicz M; Wojczal J; Szczepańska-Szerej A; Stelmasiak Z Clin Neurol Neurosurg; 2009 Oct; 111(8):676-8. PubMed ID: 19632767 [TBL] [Abstract][Full Text] [Related]
10. Cardiac time intervals by tissue Doppler imaging M-mode echocardiography: reproducibility, reference values, association with clinical characteristics and prognostic implications. Biering-Sørensen T Dan Med J; 2016 Aug; 63(8):. PubMed ID: 27477801 [TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Hamzehloo A; Etemadifar M Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351 [TBL] [Abstract][Full Text] [Related]
12. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction. Poulsen SH Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125 [TBL] [Abstract][Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
14. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636 [TBL] [Abstract][Full Text] [Related]
15. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Bernitsas E; Wei W; Mikol DD Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818 [TBL] [Abstract][Full Text] [Related]